Drugs Xagena
The FDA ( Food and Drug Administration ) has approved Veltassa ( Patiromer for oral suspension ) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.
Potassium, a mineral that is delivered to the body by food, is needed for cells to function properly. The kidneys remove potassium from the blood to maintain a proper balance of potassium in the body. But when the kidneys are not able to remove enough potassium from the blood, the level of potassium can get too high.
Hyperkalemia typically occurs in patients with acute or chronic kidney disease or heart failure, particularly in those who are taking drugs that inhibit the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance in the body.
Veltassa, a powdered medication that patients mix with water and take by mouth, works by binding potassium in the gastrointestinal tract, decreasing its absorption.
In clinical trials, Veltassa was effective in lowering potassium levels in hyperkalemic participants with chronic kidney disease on at least one drug that inhibited the renin-angiotensin-aldosterone system.
In clinical trials, the most common adverse reactions reported by participants taking Veltassa were constipation, decreased magnesium levels in the blood ( hypomagnesemia ), diarrhea, nausea, abdominal discomfort, and flatulence.
Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
Veltassa has a boxed warning because it binds many other orally administered drugs, which could decrease their absorption and reduce their effects. The warning recommends taking it and any other orally administered medication at least six hours apart.
The drug must be dispensed with a patient Medication Guide that describes important information about its uses and risks. ( Xagena )
Source: FDA, 2015
XagenaMedicine_2015
